title: MAGE-1/Heat shock protein 70/MAGE-3 fusion protein vaccine in nanoemulsion enhances cellular and humoral immune responses to MAGE-1 or MAGE-3 in vivo.
authors.affiliation: State Key Laboratory of Cancer Biology, Department of Pathology, Xi Jing Hospital, Fourth Military Medical University, Xi'an, 710032 Shaanxi Province, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Ge
authors.forename: Yan-Fang
authors.initials: YF
authors.lastname: Sui
authors.forename: Dao-Cheng
authors.initials: DC
authors.lastname: Wu
authors.forename: Yu-Jing
authors.initials: YJ
authors.lastname: Sun
authors.forename: Guang-Sheng
authors.initials: GS
authors.lastname: Chen
authors.forename: Zeng-Shan
authors.initials: ZS
authors.lastname: Li
authors.forename: Shao-Yan
authors.initials: SY
authors.lastname: Si
authors.forename: Pei-Zhen
authors.initials: PZ
authors.lastname: Hu
authors.forename: Yang
authors.initials: Y
authors.lastname: Huang
authors.forename: Xiu-Min
authors.initials: XM
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000912:Antibodies, Neoplasm / Q000096:biosynthesis / Q000276:immunology; D000917:Antibody Formation / Q000187:drug effects*; D000951:Antigens, Neoplasm / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology / Q000494:pharmacology*; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology* / Q000627:therapeutic use; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D004655:Emulsions; D004797:Enzyme-Linked Immunosorbent Assay; D018840:HSP70 Heat-Shock Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology / Q000494:pharmacology*; D007111:Immunity, Cellular / Q000187:drug effects*; D008546:Melanoma, Experimental / Q000276:immunology / Q000628:therapy*; D058950:Melanoma-Specific Antigens; D051379:Mice; D008810:Mice, Inbred C57BL; D049329:Nanostructures; D009363:Neoplasm Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology / Q000494:pharmacology*; D014677:Pharmaceutical Vehicles; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology / Q000494:pharmacology; D013047:Specific Pathogen-Free Organisms; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D004655:Emulsions; D018840:HSP70 Heat-Shock Proteins; C072011:MAGEA1 protein, human; C072013:MAGEA3 protein, human; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; D014677:Pharmaceutical Vehicles; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic